Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Website: candeltx.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 15.1% (LTM)

Entry Point: Share price is 1 265.7% higher than minimum and 27.4% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders bought company shares on $6.8 mln (3.849% of cap.)

Key Financials (Download financials)

Ticker: CADL
Share price, USD:  (+2.6%)9.22
year average price 5.31  


year start price 1.41 2024-01-06

min close price 1.21 2024-01-26

max close price 12.70 2024-05-16

current price 9.22 2025-01-05
Common stocks: 28 693 200

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 265
Net Debt ($m): -64
EV (Enterprise Value): 201
Price to Book: -17.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-12-19proactiveinvestors.com

Candel Therapeutics rides high on promising Phase 3 data, funding boost

2024-12-16globenewswire.com

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

2024-12-13proactiveinvestors.com

Candel Therapeutics unveils $80M public offering

2024-12-12globenewswire.com

Candel Therapeutics Announces Pricing of Public Offering

2024-12-12globenewswire.com

Candel Therapeutics Announces $80 Million Proposed Public Offering

2024-12-12zacks.com

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

2024-12-11seekingalpha.com

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

2024-12-11schaeffersresearch.com

Biotech Stock Hits 3-Year Highs on Trial Results

2024-12-11proactiveinvestors.com

Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer

2024-11-29proactiveinvestors.com

Candel Therapeutics is pushing for a paradigm shift in cancer treatment
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol CADL CADL CADL CADL CADL CADL CADL CADL CADL CADL
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-13 2024-05-14 2024-04-25 2023-11-09 2023-08-10 2023-05-11 2023-03-30 2022-11-10 2022-08-05
acceptedDate 2024-11-14 08:30:40 2024-08-13 08:30:22 2024-05-14 08:30:37 2024-04-25 07:33:09 2023-11-09 08:31:08 2023-08-10 08:31:21 2023-05-11 08:46:14 2023-03-30 08:46:19 2022-11-10 08:36:11 2022-08-05 08:46:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 2M 0 0 0 31 000 31 000 31 000
costOfRevenue 0 249 000 251 000 312 000 306 000 295 000 0 0 0 0
grossProfit 0 -249 000 -251 000 1M -306 000 -295 000 0 31 000 31 000 31 000
grossProfitRatio 0 0 0 0.824 0 0 0 1 1 1
researchAndDevelopmentExpenses 5M 5M 4M 7M 6M 6M 5M 5M 5M 5M
generalAndAdministrativeExpenses 3M 4M 4M 3M 3M 4M 4M 3M 4M 4M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 4M 4M 3M 3M 4M 4M 3M 4M 4M
otherExpenses 0 0 0 12 000 0 0 -12 000 -48 000 0 0
operatingExpenses 9M 9M 8M 10M 9M 10M 10M 8M 9M 9M
costAndExpenses 9M 9M 8M 10M 9M 10M 10M 8M 9M 9M
interestIncome 236 000 240 000 320 000 415 000 502 000 453 000 0 -716 000 176 000 365 000
interestExpense 487 000 567 000 646 000 673 000 -669 000 644 000 102 000 666 000 -176 000 -365 000
depreciationAndAmortization 245 000 249 000 251 000 312 000 245 000 236 000 -482 000 -3M -164 000 187 000
ebitda -10M -21M -8M -10M -9M -9M -10M -11M -9M -4M
ebitdaratio 0 0 0 -5.634 0 0 0 -348.29 -291.774 -139.581
operatingIncome -9M -9M -8M -10M -9M -10M -10M -8M -9M -9M
operatingIncomeRatio 0 0 0 -5.81 0 0 0 -261.323 -286.484 -282.355
totalOtherIncomeExpensesNet -2M -14M -319 000 -777 000 581 000 144 000 838 000 3M 193 000 5M
incomeBeforeTax -11M -22M -8M -11M -8M -10M -9M -5M -9M -4M
incomeBeforeTaxRatio 0 0 0 -6.247 0 0 0 -163.968 -280.258 -133.839
incomeTaxExpense 0 0 207 724 386 000 -90 000 644 000 -940 000 -16M -193 000 0
netIncome -11M -22M -8M -11M -8M -10M -8M 11M -8M -4M
netIncomeRatio 0 0 0 -6.247 0 0 0 343.613 -274.032 -133.839
eps -0.33 -0.74 -0.28 -0.38 -0.29 -0.33 -0.27 0.37 -0.29 -0.14
epsdiluted -0.33 -0.74 -0.28 -0.38 -0.29 -0.33 -0.27 0.37 -0.29 -0.14
weightedAverageShsOut 32M 30M 29M 29M 29M 29M 29M 29M 29M 29M
weightedAverageShsOutDil 32M 30M 29M 29M 29M 29M 29M 29M 29M 29M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol CADL CADL CADL CADL CADL CADL CADL CADL CADL CADL
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-13 2024-05-14 2024-04-25 2023-11-09 2023-08-10 2023-05-11 2023-03-30 2022-11-10 2022-08-05
acceptedDate 2024-11-14 08:30:40 2024-08-13 08:30:22 2024-05-14 08:30:37 2024-04-25 07:33:09 2023-11-09 08:31:08 2023-08-10 08:31:21 2023-05-11 08:46:14 2023-03-30 08:46:19 2022-11-10 08:36:11 2022-08-05 08:46:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 17M 21M 26M 35M 43M 52M 59M 70M 77M 87M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 17M 21M 26M 35M 43M 52M 59M 70M 77M 87M
netReceivables 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 2M 1M 1M 1M 2M 1M 3M 2M 2M 544 000
totalCurrentAssets 18M 23M 27M 37M 45M 53M 62M 72M 79M 87M
propertyPlantEquipmentNet 3M 3M 4M 4M 5M 5M 5M 5M 6M 6M
goodwill 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 266 000 266 000 266 000 266 000 0 0 0 0
taxAssets 0 0 0 501 000 0 0 0 0 0 0
otherNonCurrentAssets 341 000 347 000 101 999 116 000 139 000 159 000 266 000 266 000 266 000 266 000
totalNonCurrentAssets 3M 4M 4M 5M 5M 5M 5M 6M 6M 6M
otherAssets 0 0 1 0 0 0 0 0 0 0
totalAssets 22M 26M 31M 42M 50M 59M 67M 78M 85M 93M
accountPayables 296 000 433 000 472 000 422 000 250 000 480 000 592 000 380 000 970 000 2M
shortTermDebt 10M 11M 10M 9M 7M 4M 2M 464 000 452 000 440 000
taxPayables 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 108 000 120 000 132 000 144 000 0 0
otherCurrentLiabilities 5M 3M 3M 4M 3M 3M 3M 5M 4M 4M
totalCurrentLiabilities 15M 14M 14M 14M 10M 8M 5M 6M 6M 6M
longTermDebt 6M 8M 10M 12M 16M 19M 21M 22M 22M 22M
deferredRevenueNonCurrent 0 0 0 973 000 108 000 120 000 132 000 144 000 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 501 000 -14M -17M 0 0 0 0
otherNonCurrentLiabilities 16M 14M 2M 916 000 15M 18M 1M 2M 26M 5M
totalNonCurrentLiabilities 22M 22M 12M 15M 17M 20M 22M 24M 27M 27M
otherLiabilities 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 555 000 1M 837 000 973 000 2M 2M 2M 2M 2M 2M
totalLiabilities 37M 36M 25M 29M 27M 28M 28M 30M 33M 33M
preferredStock 0 0 1 0 0 0 0 0 0 0
commonStock 322 000 303 000 292 000 290 000 290 000 290 000 290 000 290 000 290 000 290 000
retainedEarnings -178M -167M -145M -137M -126M -117M -108M -99M -94M -85M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 -0 0 0 0 0 0 0
othertotalStockholdersEquity 163M 157M 151M 149M 149M 148M 147M -290 000 146M 145M
totalStockholdersEquity -15M -10M 6M 13M 23M 31M 40M -99M 52M 60M
totalEquity -15M -10M 6M 13M 23M 31M 40M -99M 52M 60M
totalLiabilitiesAndStockholdersEquity 22M 26M 31M 42M 50M 59M 67M -69M 85M 93M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 22M 26M 31M 42M 50M 59M 67M -69M 85M 93M
totalInvestments 0 266 000 266 000 266 000 266 000 266 000 0 0 0 0
totalDebt 16M 19M 21M 23M 23M 23M 23M 23M 23M 23M
netDebt -535 000 -3M -5M -13M -20M -29M -36M -47M -54M -64M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol CADL CADL CADL CADL CADL CADL CADL CADL CADL CADL
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-13 2024-05-14 2024-04-25 2023-11-09 2023-08-10 2023-05-11 2023-03-30 2022-11-10 2022-08-05
acceptedDate 2024-11-14 08:30:40 2024-08-13 08:30:22 2024-05-14 08:30:37 2024-04-25 07:33:09 2023-11-09 08:31:08 2023-08-10 08:31:21 2023-05-11 08:46:14 2023-03-30 08:46:19 2022-11-10 08:36:11 2022-08-05 08:46:43
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -11M -22M -8M -11M -8M -10M -9M -5M -9M -4M
depreciationAndAmortization 245 000 249 000 251 000 312 000 245 000 236 000 230 000 221 000 205 000 187 000
deferredIncomeTax 0 0 0 -1M -416 000 -144 000 0 0 0 0
stockBasedCompensation 1M 2M 1M 939 000 686 000 733 000 733 000 634 000 743 000 438 000
changeInWorkingCapital 844 000 441 000 -2M 2M -1M 1M -2M -71 000 -1M 1M
accountsReceivables 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0
accountsPayables -140 000 -39 000 50 000 172 000 -214 000 -62 000 149 000 -544 000 -508 000 418 000
otherWorkingCapital 984 000 480 000 -2M 1M -844 000 1M -3M 473 000 -937 000 -32 000
otherNonCashItems 2M 14M 2M 2M 170 000 163 000 -492 000 -3M -199 000 -5M
netCashProvidedByOperatingActivities -7M -6M -8M -7M -9M -7M -11M -7M -9M -7M
investmentsInPropertyPlantAndEquipment 0 -6000 -7000 -47 000 -103 000 -169 000 -138 000 -276 000 -215 000 -635 000
acquisitionsNet 0 0 0 20 000 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 20 000 0 0 157 000 0 0 0
netCashUsedForInvestingActivites 0 -6000 -7000 -27 000 -103 000 -169 000 19 000 -276 000 -215 000 -635 000
debtRepayment -3M -3M -2M 0 0 0 0 0 0 0
commonStockIssued 4M 3M 412 000 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 -121 000 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 103 000 990 000 -1M -121 000 0 0 0 36 000 0 22 000
netCashUsedProvidedByFinancingActivities 2M 2M -1M -121 000 0 0 0 36 000 0 22 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0
netChangeInCash -5M -4M -10M -8M -9M -7M -11M -7M -10M -8M
cashAtEndOfPeriod 17M 21M 26M 35M 43M 52M 60M 70M 77M 87M
cashAtBeginningOfPeriod 21M 26M 35M 43M 52M 60M 70M 77M 87M 95M
operatingCashFlow -7M -6M -8M -7M -9M -7M -11M -7M -9M -7M
capitalExpenditure 0 -6000 -7000 -47 000 -103 000 -169 000 -138 000 -276 000 -215 000 -635 000
freeCashFlow -7M -6M -8M -7M -9M -7M -11M -7M -10M -8M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-14 13:00 ET
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
2024-11-07 13:00 ET
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
2024-11-05 14:00 ET
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
2024-10-28 12:00 ET
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
2024-10-04 13:00 ET
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
2024-09-03 12:00 ET
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
2024-08-13 12:00 ET
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
2024-06-18 12:00 ET
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
2024-06-14 12:30 ET
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
2024-06-11 12:00 ET
Candel Therapeutics to Join Russell 3000® Index
2024-06-07 12:30 ET
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
2024-06-03 12:30 ET
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
2024-05-30 12:00 ET
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
2024-05-23 21:00 ET
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
2024-05-22 12:00 ET
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
2024-05-20 12:00 ET
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
2024-05-14 12:00 ET
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
2024-04-25 12:00 ET
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
2024-04-11 13:00 ET
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
2024-04-09 12:00 ET
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
2024-04-04 12:00 ET
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2024-03-28 20:05 ET
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
2024-03-28 12:05 ET
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
2024-03-15 12:15 ET
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
2024-03-15 12:15 ET
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
2024-03-05 21:30 ET
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
2024-02-28 13:15 ET
Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
2024-02-28 13:15 ET
Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
2024-02-15 13:25 ET
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
2024-02-13 12:30 ET
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
2024-02-05 13:00 ET
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
2023-12-12 13:00 ET
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
2023-11-28 14:00 ET
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
2023-11-09 13:00 ET
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-04 12:00 ET
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
2023-11-03 16:00 ET
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2023-10-18 15:00 ET
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
2023-09-27 13:40 ET
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
2023-09-26 12:00 ET
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
2023-09-06 12:00 ET
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 12:00 ET
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-02 12:00 ET
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
2023-06-13 12:00 ET
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
2023-06-08 12:00 ET
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
2023-06-05 12:00 ET
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
2023-05-19 13:00 ET
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
2023-05-11 12:00 ET
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-02 12:00 ET
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
2023-04-17 12:00 ET
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
2023-03-30 12:00 ET
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
2023-02-01 13:00 ET
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
2023-01-12 13:00 ET
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
2022-12-06 21:26 ET
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
2022-11-29 13:00 ET
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
2022-11-18 13:00 ET
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
2022-11-11 17:00 ET
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
2022-11-10 13:00 ET
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
2022-11-07 13:00 ET
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
2022-11-01 12:00 ET
Candel Therapeutics Upcoming Investor Conference Participation for November
2022-10-26 12:00 ET
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
2022-09-15 12:00 ET
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
2022-09-07 12:00 ET
Candel Therapeutics Announces Two Executive Leadership Appointments
2022-09-06 12:00 ET
Candel Therapeutics Upcoming Investor Conference Participation
2022-08-05 12:00 ET
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
2022-08-01 12:00 ET
Candel Therapeutics Appoints Three New Members to its Board of Directors
2022-05-26 21:30 ET
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
2022-05-18 12:00 ET
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
2022-05-12 12:00 ET
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
2022-04-27 20:00 ET
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-03-29 12:00 ET
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
2022-03-02 13:00 ET
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
2022-03-01 13:00 ET
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
2022-02-03 13:00 ET
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
2022-01-05 13:00 ET
Candel Therapeutics to Present at Two Upcoming Investor Conferences
2021-12-15 10:00 ET
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies
2021-12-10 13:00 ET
Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409
2021-11-12 13:00 ET
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
2021-11-12 13:00 ET
Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma
2021-11-02 12:00 ET
Candel Therapeutics to Participate in Three Upcoming Investor Conferences
2021-11-01 12:00 ET
Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies
2021-10-28 12:00 ET
Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer 
2021-10-19 12:00 ET
Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer
2021-10-04 12:00 ET
Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
2021-10-01 12:00 ET
Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies
2021-09-09 12:00 ET
Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021
2021-09-08 12:00 ET
Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
2021-09-07 12:00 ET
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
2021-08-17 12:00 ET
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
2021-07-27 01:05 ET
Candel Therapeutics Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-11-14 08:30 ET
Candel Therapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Candel Therapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Candel Therapeutics, Inc. published news for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Candel Therapeutics, Inc. published news for 2024 q3
SEC form 10
2024-08-13 08:30 ET
Candel Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Candel Therapeutics, Inc. published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Candel Therapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Candel Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-14 08:30 ET
Candel Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-14 08:15 ET
Candel Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-05-14 08:15 ET
Candel Therapeutics, Inc. published news for 2024 q1
SEC form 10
2024-05-14 00:00 ET
Candel Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-28 08:00 ET
Candel Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-28 07:45 ET
Candel Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-03-28 07:45 ET
Candel Therapeutics, Inc. published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Candel Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-09 08:31 ET
Candel Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-09 08:16 ET
Candel Therapeutics, Inc. published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Candel Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-10 08:31 ET
Candel Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-10 08:15 ET
Candel Therapeutics, Inc. published news for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Candel Therapeutics, Inc. published news for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Candel Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-06-29 08:31 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-13 08:31 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-23 08:00 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-11 08:46 ET
Candel Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-11 08:31 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Candel Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-09 17:02 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-01 08:01 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-17 08:30 ET
Candel Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-30 08:46 ET
Candel Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-30 08:30 ET
Candel Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Candel Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-30 00:00 ET
Candel Therapeutics, Inc. reported for 2022 q4
SEC form 10
2022-11-10 00:00 ET
Candel Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Candel Therapeutics, Inc. published news for 2022 q3
SEC form 8
2022-08-05 00:00 ET
Candel Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Candel Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-05-12 00:00 ET
Candel Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Candel Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-03-29 00:00 ET
Candel Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-29 00:00 ET
Candel Therapeutics, Inc. published news for 2021 q4
SEC form 8
2021-11-12 00:00 ET
Candel Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Candel Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-09-08 00:00 ET
Candel Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-09-08 00:00 ET
Candel Therapeutics, Inc. published news for 2021 q2